[HTML][HTML] The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer
X Wang, W Qiu, H Liu, M He, W He, Z Li… - Cancer Biology & …, 2023 - ncbi.nlm.nih.gov
Objective: CAR-T/NK cells have had limited success in the treatment of solid tumors, such as
colorectal cancer (CRC), in part because of the heterogeneous nature of tumor-associated …
colorectal cancer (CRC), in part because of the heterogeneous nature of tumor-associated …
In vivo characterization of a novel CAR-T cell therapy directed towards LGR5 for the treatment of colorectal cancer
DJ McPeake, TS Tyllis, J Foeng, V Bandara, CA Abbott… - Cancer Research, 2022 - AACR
Colorectal cancer (CRC) is the third most diagnosed cancer and incidence rates are rapidly
increasing among young adults. Despite current treatments, the 5-year survival rate is …
increasing among young adults. Despite current treatments, the 5-year survival rate is …
Abstract B094: intratumoral administration of IMO-2125, a novel TLR9 agonist, modulates the tumor microenvironment and exerts systemic antitumor activity alone and …
D Wang, F Zhu, X Mao, S Agrawal - Cancer Immunology Research, 2016 - AACR
Cancer immunotherapy aims to stimulate host antitumor immune responses or break tumor-
related immune tolerance or both with the potential of curative treatment. Potential …
related immune tolerance or both with the potential of curative treatment. Potential …
CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer
M Li, S Li, R Zhao, J Lv, D Zheng, L Qin, S Li… - Clinical and …, 2023 - Springer
Colorectal cancer (CRC) currently has a poor prognosis with a 6.9-year median survival
time; to relieve this malignant cancer, we proposed to establish CRC xenografts that can be …
time; to relieve this malignant cancer, we proposed to establish CRC xenografts that can be …
DCLK1 monoclonal antibody-based CAR-T cells as a novel treatment strategy against human colorectal cancers
SM Sureban, R Berahovich, H Zhou, S Xu, L Wu… - Cancers, 2019 - mdpi.com
CAR-T (chimeric antigen receptor T cells) immunotherapy is effective in many hematological
cancers; however, efficacy in solid tumors is disappointing. Doublecortin-like kinase 1 …
cancers; however, efficacy in solid tumors is disappointing. Doublecortin-like kinase 1 …
Pre-activation with TLR7 in combination with thioridazine and loratadine promotes tumoricidal T-cell activity in colorectal cancer
X Lin, J Zhang, X Wang, G Lin, T Chen - Anti-Cancer Drugs, 2020 - journals.lww.com
Colorectal cancer (CRC) is the third most common malignancy worldwide. Our previous
studies have shown that combinatorial treatment with thioridazine and loratadine may …
studies have shown that combinatorial treatment with thioridazine and loratadine may …
A phase 1/2a, multicenter, open-label study of CNA3103 (LGR5-targeted, autologous CAR-T cells) in patients with metastatic colorectal cancer (mCRC).
TPS3632 Background: Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5)
is a cancer stem cell (CSC) marker that is abundant in solid tumors, highly expressed in …
is a cancer stem cell (CSC) marker that is abundant in solid tumors, highly expressed in …
[HTML][HTML] CD166-specific CAR-T cells potently target colorectal cancer cells
S He, S Li, J Guo, X Zeng, D Liang, Y Zhu, Y Li… - Translational …, 2023 - Elsevier
Chimeric antigen receptor (CAR) T-cell therapy is emerging as an effective cancer treatment,
such as for hematological malignancies, however its effectiveness as an approach to treat …
such as for hematological malignancies, however its effectiveness as an approach to treat …
Abstract B196: intratumoral administration of IMO-2125, a novel TLR9 agonist, modulates tumor microenvironment and potentiates antitumor activity of anti-PD-1 mAb …
D Wang, F Zhu, J DiMuzio, S Agrawal - Molecular Cancer Therapeutics, 2015 - AACR
Immunotherapeutic advances in the treatment of cancer by targeting immune checkpoint
pathways has shown promising results, however, data for agents currently in development …
pathways has shown promising results, however, data for agents currently in development …
Abstract A48: Therapeutic targeting of colorectal cancer stem cells with BNC101, a functional anti-LGR5 monoclonal antibody.
P Chu, K Smith, F Shojaei, C Walsh, J Norton… - Molecular Cancer …, 2013 - AACR
BNC101 is a monoclonal antibody that targets LGR5, a validated cancer stem cell (CSC)
receptor overexpressed in colorectal cancer (CRC) and most other solid tumors. Loss and …
receptor overexpressed in colorectal cancer (CRC) and most other solid tumors. Loss and …
